Higashiosaka, Japan

Hiroyuki Iwai


Average Co-Inventor Count = 3.7

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Settsu, JP (1989)
  • Higashi-Osaka, JP (1992)

Company Filing History:


Years Active: 1989-1992

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hiroyuki Iwai: Innovator in Carcinostatic Substances

Introduction

Hiroyuki Iwai is a notable inventor based in Higashiosaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic potential. With a total of 2 patents to his name, Iwai's work focuses on improving the efficacy and safety of cancer treatments.

Latest Patents

One of Iwai's latest patents involves a novel fluorine-containing platinum complex. This complex is designed to produce 5-fluorouracil derivatives that are useful as carcinostatic substances. The specific derivative he has developed is characterized by the formula: ##STR1##, where R.sup.1 is a fluorine-containing C.sub.1 -C.sub.10 organic group that may optionally include sulfur, oxygen, and/or nitrogen. This innovative derivative demonstrates high carcinostatic activity while exhibiting lower toxicity against the digestive tract, thus causing less autonomic imbalance compared to other known 5-fluorouracil derivatives.

Career Highlights

Hiroyuki Iwai is currently employed at Daikin Industries, Ltd., where he continues to advance his research in the field of medicinal chemistry. His work is pivotal in the ongoing quest to develop safer and more effective cancer therapies.

Collaborations

Iwai collaborates with esteemed colleagues such as Kazuhiro Shimokawa and Tsuneo Yamashita. Their combined expertise contributes to the innovative research and development efforts at their organization.

Conclusion

Hiroyuki Iwai's contributions to the field of pharmaceuticals, particularly in the development of novel carcinostatic substances, highlight his role as a significant inventor. His work not only aims to enhance treatment efficacy but also prioritizes patient safety.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…